Eli Lilly's Mounjaro, Zepbound to remain in shortage through end of Q2 [Seeking Alpha]
Novo Nordisk A/S (NVO)
Last novo nordisk a/s earnings: 2/5 01:31 am
Check Earnings Report
US:NYSE Investor Relations:
novonordisk.com/investors.html
Company Research
Source: Seeking Alpha
The U.S. FDA Wednesday updated the drug shortage status for the two medications. Only one dosage strength of Mounjaro and Zepbound have normal availability. Tirzepatide, a dual GIP/GLP-1 receptor co-agonist, has proven to be one of Lilly's most successful recent drug launches . While the drug more recently won approval as a weight loss therapy (Zepbound), Mounjaro was being used off label for weight loss prior. Novo Nordisk's ( NVO ) competing GLP-1 weight loss therapy, Wegovy (semaglutide), is also in shortage, with four out of five dosage strengths having limited availability. The FDA said that the estimated shortage duration is to be determined. Ozempic, which also contains semaglutide but is approved for diabetes, is not in shortage. Recommended For You More Trending News Recommended For You More Trending News
Show less
Read more
Impact Snapshot
Event Time:
NVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVO alerts
High impacting Novo Nordisk A/S news events
Weekly update
A roundup of the hottest topics
NVO
News
- Molson Coors Says ‘Volatile Times,' Not Ozempic, Dim Its Beer Outlook [BNN Bloomberg (Canada)]BNN Bloomberg
- European Stocks Slip as Hot US Wage Inflation Fuels Hawkish Bets [Financial Post (Toronto, Ontario, Canada)]Financial Post
- FTC Warns ‘Junk Patents' Could Make Drugs Like Ozempic Pricier—Here's How [Forbes]Forbes
- European Stocks Slip as Hot US Wage Inflation Fuels Hawkish Bets [BNN Bloomberg (Canada)]BNN Bloomberg
- FTC challenges ‘junk' patents held by 10 drugmakers, including for Novo Nordisk's Ozempic [CNBC]CNBC
NVO
Earnings
- 11/3/23 - Beat
NVO
Sec Filings
- 4/26/24 - Form 6-K
- 4/25/24 - Form 6-K
- 4/25/24 - Form 6-K
- NVO's page on the SEC website